Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV.

Ebrahim I, Maartens G, Wiesner L, Orrell C, Smythe W, McIlleron H.

J Antimicrob Chemother. 2020 Jan 13. pii: dkz522. doi: 10.1093/jac/dkz522. [Epub ahead of print]

PMID:
31942627
2.

CORRELATION OF LINEZOLID HAIR CONCENTRATIONS WITH PLASMA EXPOSURE IN PATIENTS WITH DRUG-RESISTANT TB.

Wasserman S, Huo S, Ky K, Malig YN, Esmail A, Dheda K, Bacchetti P, Gerona R, Maartens G, Gandhi M, Metcalfe J.

Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02145-19. doi: 10.1128/AAC.02145-19. [Epub ahead of print]

PMID:
31932382
3.

Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis.

Antel K, Oosthuizen J, Malherbe F, Louw VJ, Nicol MP, Maartens G, Verburgh E.

BMC Infect Dis. 2020 Jan 13;20(1):33. doi: 10.1186/s12879-019-4749-x.

4.

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus associated tuberculosis.

Schutz C, Chirehwa M, Barr D, Ward A, Janssen S, Burton R, Wilkinson RJ, Shey M, Wiesner L, Denti P, McIlleron H, Maartens G, Meintjes G.

Br J Clin Pharmacol. 2020 Jan 7. doi: 10.1111/bcp.14207. [Epub ahead of print]

PMID:
31912537
5.

Safety and Effectiveness of Isoniazid Preventive Therapy in HIV-Positive Pregnant Women on Art: An Observational Study using Linked Population Data.

Kalk E, Heekes A, Mehta U, de Waal R, Jacob N, Cohen K, Myer L, Davies MA, Maartens G, Boulle A.

Clin Infect Dis. 2020 Jan 4. pii: ciz1224. doi: 10.1093/cid/ciz1224. [Epub ahead of print]

PMID:
31900473
6.

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.

Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, Gumbo T, McIlleron H, Ramma L.

Int J Audiol. 2019 Nov 18:1-5. doi: 10.1080/14992027.2019.1690170. [Epub ahead of print]

PMID:
31739701
7.

Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Court R, Chirehwa MT, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1068-1074. doi: 10.5588/ijtld.18.0775.

PMID:
31627771
8.

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals.

Van Hoving DJ, Griesel R, Meintjes G, Takwoingi Y, Maartens G, Ochodo EA.

Cochrane Database Syst Rev. 2019 Sep 30;9:CD012777. doi: 10.1002/14651858.CD012777.pub2.

9.

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group.

Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Review.

PMID:
31486393
10.

A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis.

Cohen K, Maartens G.

Expert Opin Drug Saf. 2019 Oct;18(10):875-882. doi: 10.1080/14740338.2019.1648429. Epub 2019 Aug 5. Review.

PMID:
31339384
11.

Etiology of Pulmonary Infections in Human Immunodeficiency Virus-infected Inpatients Using Sputum Multiplex Real-time Polymerase Chain Reaction.

Maartens G, Griesel R, Dube F, Nicol M, Mendelson M.

Clin Infect Dis. 2019 Apr 26. pii: ciz332. doi: 10.1093/cid/ciz332. [Epub ahead of print]

PMID:
31286137
12.

Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study.

Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, Burton R, Wilkinson KA, Sossen B, Fukutani KF, Nicol M, Maartens G, Wilkinson RJ, Meintjes G.

PLoS Med. 2019 Jul 5;16(7):e1002840. doi: 10.1371/journal.pmed.1002840. eCollection 2019 Jul.

13.

Management of active tuberculosis in adults with HIV.

Meintjes G, Brust JCM, Nuttall J, Maartens G.

Lancet HIV. 2019 Jul;6(7):e463-e474. doi: 10.1016/S2352-3018(19)30154-7. Review.

PMID:
31272663
14.

Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.

Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K.

BMC Infect Dis. 2019 Jun 20;19(1):544. doi: 10.1186/s12879-019-4197-7.

15.

Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.

Banda CG, Barnes KI, Maartens G.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00576-19. doi: 10.1128/AAC.00576-19. Print 2019 Jun. No abstract available.

16.

Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa.

Takuva S, Nabyoma JM, Dawood H, Black A, Maartens G, Parrish A, Leong TD.

S Afr Med J. 2019 Mar 29;109(4):198-199. doi: 10.7196/SAMJ.2019.v109i4.13877. No abstract available.

17.

Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.

Wasserman S, Louw G, Ramangoaela L, Barber G, Hayes C, Omar SV, Maartens G, Barry C, Song T, Meintjes G.

J Antimicrob Chemother. 2019 Aug 1;74(8):2377-2384. doi: 10.1093/jac/dkz206.

18.

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans.

Johnston J, Wiesner L, Smith P, Maartens G, Orrell C.

South Afr J HIV Med. 2019 Apr 29;20(1):881. doi: 10.4102/sajhivmed.v20i1.881. eCollection 2019.

19.

Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS. Reply.

Meintjes G, Stek C, Maartens G.

N Engl J Med. 2019 May 2;380(18):1781. doi: 10.1056/NEJMc1900116. No abstract available.

PMID:
31042844
20.

The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting.

Antel K, Levetan C, Mohamed Z, Louw VJ, Oosthuizen J, Maartens G, Verburgh E.

BMC Cancer. 2019 Apr 25;19(1):384. doi: 10.1186/s12885-019-5586-4.

21.

Abdominal Ultrasound for the Diagnosis of Tuberculosis Among Human Immunodeficiency Virus-Positive Inpatients With World Health Organization Danger Signs.

Griesel R, Cohen K, Mendelson M, Maartens G.

Open Forum Infect Dis. 2019 Apr 7;6(4):ofz094. doi: 10.1093/ofid/ofz094. eCollection 2019 Apr.

22.

Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.

Wang X, Cerrone M, Ferretti F, Castrillo N, Maartens G, McClure M, Boffito M.

Int J Antimicrob Agents. 2019 Aug;54(2):202-206. doi: 10.1016/j.ijantimicag.2019.04.009. Epub 2019 Apr 16.

PMID:
31002950
23.

Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found To Be on Antiretroviral Therapy.

Sykes W, Van den Berg K, Jacobs G, Jauregui A, Roubinian N, Wiesner L, Maartens G, Swanevelder R, Custer B, Busch M, Jentsch U, Murphy EL, Vermeulen M; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).

J Infect Dis. 2019 Jul 19;220(4):643-647. doi: 10.1093/infdis/jiz145.

24.

Emtricitabine-associated red cell aplasia.

Cohen K, Viljoen C, Njuguna C, Maartens G.

AIDS. 2019 May 1;33(6):1095-1096. doi: 10.1097/QAD.0000000000002136.

PMID:
30946164
25.

Managing HIV-associated tuberculosis in the dolutegravir era.

Maartens G, Meintjes G.

Clin Infect Dis. 2019 Mar 25. pii: ciz259. doi: 10.1093/cid/ciz259. [Epub ahead of print] No abstract available.

PMID:
30906946
26.

A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.

Phillips TK, Sinxadi P, Abrams EJ, Zerbe A, Orrell C, Hu NC, Brittain K, Gomba Y, Norman J, Wiesner L, Myer L, Maartens G.

J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):311-318. doi: 10.1097/QAI.0000000000002032.

PMID:
30893125
27.

Brief Report: Real-World Performance and Interobserver Agreement of Urine Lipoarabinomannan in Diagnosing HIV-Associated Tuberculosis in an Emergency Center.

Van Hoving DJ, Lahri S, Lategan HJ, Nicol MP, Maartens G, Meintjes G.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):e10-e14. doi: 10.1097/QAI.0000000000002002.

PMID:
30865176
28.

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, Maartens G, Pozniak A, Flexner C, Boffito M.

J Antimicrob Chemother. 2019 Jun 1;74(6):1670-1678. doi: 10.1093/jac/dkz068.

PMID:
30815689
29.

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.

Wasserman S, Denti P, Brust JCM, Abdelwahab M, Hlungulu S, Wiesner L, Norman J, Sirgel FA, Warren RM, Esmail A, Dheda K, Gandhi NR, Meintjes G, Maartens G.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02164-18. doi: 10.1128/AAC.02164-18. Print 2019 Mar.

30.

Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Decloedt EH, Sinxadi PZ, van Zyl GU, Wiesner L, Khoo S, Joska JA, Haas DW, Maartens G.

J Antimicrob Chemother. 2019 Mar 1;74(3):699-709. doi: 10.1093/jac/dky481.

31.

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy.

Cohen K, Stewart A, Kengne AP, Leisegang R, Coetsee M, Maharaj S, Dunn L, Hislop M, van Zyl G, Meintjes G, Maartens G.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):325-329. doi: 10.1097/QAI.0000000000001923.

PMID:
30531296
32.

Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements.

Wilson D, Moosa MS, Cohen T, Cudahy P, Aldous C, Maartens G.

Open Forum Infect Dis. 2018 Oct 10;5(11):ofy253. doi: 10.1093/ofid/ofy253. eCollection 2018 Nov.

33.

Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.

Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team.

N Engl J Med. 2018 Nov 15;379(20):1915-1925. doi: 10.1056/NEJMoa1800762.

34.

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.

Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801528. doi: 10.1183/13993003.01528-2018. Print 2018 Dec.

PMID:
30361246
35.

Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):564-571. doi: 10.1164/rccm.201806-1053PP. No abstract available.

36.

Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.

Moorhouse M, Maartens G, Venter WDF, Moosa MY, Steegen K, Jamaloodien K, Fox MP, Conradie F.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):73-78. doi: 10.1097/QAI.0000000000001883.

37.

Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.

Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX.

AIDS. 2019 Mar 1;33(3):525-536. doi: 10.1097/QAD.0000000000002053.

38.

The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries.

Pillai G, Chibale K, Constable EC, Keller AN, Gutierrez MM, Mirza F, Sengstag C, Masimirembwa C, Denti P, Maartens G, Ramsay M, Ogutu B, Makonnen E, Gordon R, Ferreira CG, Goldbaum FA, Degrave WMS, Spector J, Tadmor B, Kaiser HJ.

BMC Med Educ. 2018 Oct 10;18(1):233. doi: 10.1186/s12909-018-1331-y.

39.

Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1.

Lesosky M, Rangaka MX, Pienaar C, Coussens AK, Goliath R, Mathee S, Mwansa-Kambafwile J, Maartens G, Wilkinson RJ, Wilkinson KA.

Clin Infect Dis. 2019 Jul 2;69(2):295-305. doi: 10.1093/cid/ciy823.

40.

Erratum to South African guideline for the management of community-acquired pneumonia in adults.

Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Richards GA, van Zyl Smit R, Smith C, Wasserman S, Whitelaw AC, Feldman C; South African Thoracic Society; Federation of Infectious Diseases Societies of Southern Africa.

J Thorac Dis. 2018 Aug;10(8):E673-E675. doi: 10.21037/jtd.2018.07.137.

41.

Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts.

de Waal R, Cohen K, Boulle A, Fox MP, Maartens G, Igumbor EU, Davies MA.

PLoS One. 2018 Sep 5;13(9):e0203530. doi: 10.1371/journal.pone.0203530. eCollection 2018.

42.

Development of a clinical prediction rule to diagnose Pneumocystis jirovecii pneumonia in the World Health Organization's algorithm for seriously ill HIV-infected patients.

Maartens G, Stewart A, Griesel R, Kengne AP, Dube F, Nicol M, Rangaka MX, Mendelson M.

South Afr J HIV Med. 2018 Jul 23;19(1):851. doi: 10.4102/sajhivmed.v19i1.851. eCollection 2018.

43.

Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV.

Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G.

Int J Infect Dis. 2018 Oct;75:67-73. doi: 10.1016/j.ijid.2018.08.005. Epub 2018 Aug 17.

44.
45.

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.

Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Padanilam X, Romero R, Te Riele J, Conradie F.

Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11.

PMID:
30001994
46.

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Court RG, Wiesner L, Chirehwa MT, Stewart A, de Vries N, Harding J, Gumbo T, McIlleron H, Maartens G.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):926-930. doi: 10.5588/ijtld.18.0091.

47.

Anthropometric definitions for antiretroviral-associated lipodystrophy derived from a longitudinal South African cohort with serial dual-energy X-ray absorptiometry measurements.

Abrahams Z, Maartens G, Levitt N, Dave J.

Int J STD AIDS. 2018 Oct;29(12):1194-1203. doi: 10.1177/0956462418778649. Epub 2018 Jun 26.

PMID:
29945538
48.

Prognostic indicators in the World Health Organization's algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis.

Griesel R, Stewart A, van der Plas H, Sikhondze W, Mendelson M, Maartens G.

AIDS Res Ther. 2018 Feb 12;15(1):5. doi: 10.1186/s12981-018-0192-0.

49.

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, Gumbo T, McIlleron H.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):30-33. doi: 10.5588/ijtld.17.0475.

50.

Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.

Maartens G, Brill MJE, Pandie M, Svensson EM.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):26-29. doi: 10.5588/ijtld.17.0615. Epub 2017 Nov 16.

PMID:
29145924

Supplemental Content

Loading ...
Support Center